ArticleJournal of medical cases2025
Treatment of Invasive Fungal Disease During Therapy for Acute Lymphoblastic Leukemia.
Article in Journal of medical cases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive fungal diseases (IFDs) are one of the leading causes of death in acute leukemia (AL) patients. Because of the possibility of fungal relapse, patients who survive IFDs may have difficulty in completing the whole chemotherapy plan. Our case report presents two cases of IFD with aspergillosis in children with precursor B-cell acute lymphoblastic leukemia (pre-B-ALL). Two 9-year-old female patients were diagnosed with pre-B-ALL that were on the pre-B-ALL protocol: CALL08, Arm-C (high-risk arm), and the supportive therapy. They were both on Arm-C of the CALL08 protocol (high risk based on COG232). Then, the patients experienced severe febrile neutropenia. Patient 1 was during consolidation, and patient 2 was during interim maintenance I. Both experienced prolonged febrile neutropenia. As febrile neutropenia continued for more than 5 days, a fungal workup was conducted, including computed tomography (CT) scans of the sinuses, chest, and abdomen, as well as serum tests for galactomannan and (1→3)-β-D-glucan (BDG). Caspofungin treatment was started. Fungal workup results showed lung and liver nodules in one patient and lungs, liver, and spleen in the other. There were about 4 weeks of severe fevers and neutropenia, despite the use of broad-spectrum antibiotics. A decision was taken to interrupt chemotherapy for both patients. Voriconazole was added to caspofungin. Biopsies confirmed the diagnosis to be severe fungal infection with invasive aspergillosis. After that, high fevers and neutropenia slowly recovered, and a repeated CT scan of abdomen showed good improvement in the lesion's number and size. After 6 - 8 weeks of interruption, chemotherapy was resumed. We observed that with the implementation of combination antifungal therapy with voriconazole and caspofungin for 6 weeks and then single antifungal therapy (voriconazole orally) for another 6 weeks, both patients recovered and became clinically stable and afebrile. Chemotherapy was on hold till they became better. In conclusion, primary and secondary antifungal prophylaxis are recommended for ALL patients. Chemotherapy discontinuation is decided on an individual basis according to the severity of the fungal infection and disease status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.